Clinical Trials Logo
  1. Home
  2. Post Partum Hemorrhage
  3. NCT03907605
  4. Details
NCT03907605 Clinical Trial

Anti-Mullerian Hormone (AMH) is a Marker for Ovarian Reserve. There Are Many Studies About AMH Changes in Ovarian Surgery, But Little is Known for Other Surgeries. We Seek to Investigate the Hormone Variations Before and After Uterine Artey Ligation for Postpartum Hemorrage (PPH)

Post Partum Hemorrhage Clinical Trial

Official title:
Comparison of Serum Anti-Mullerian Hormone Levels Following Uterine Artery Ligation for PPH.

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03907605
Other study ID # amhpph
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2018
Est. completion date April 1, 2019

Study information
Verified date April 2019
Source Kanuni Sultan Suleyman Training and Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Anti-Mullerian hormone (AMH) is a marker for ovarian reserve. There are many studies about AMH changes in ovarian surgery, but little is known for other surgeries. We seek to investigate the hormone variations before and after uterine artey ligation for postpartum hemorrage (PPH)

Description:

All patients belong to the same group. The blood samples will be collected at the time of surgery and 3 months after surgery from the patients who need uterine artery ligation for PPH. The blood samples will be centrifuged within 2 hours after being obtained and assessed on the same day. AMH concentrations will be measured with an enzymatically amplified two-sided immunoassay

Recruitment information / eligibility
Status Completed
Enrollment 88
Est. completion date April 1, 2019
Est. primary completion date March 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- age 18- 40 years

- no systemic or endocrine diseases

- patients who had uterine artery ligation due to PPH

Exclusion Criteria:

- Pregnancy with IVF or oosit donation

- Patients with endocrinopathy, diseases which require radiotherapy and chemotherapy etc.

- Patients with BMI >40

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• anti- mullerian hormone
All patients belong to the same group. The blood samples will be collected at the time of surgery and 3 months after surgery from the patients who need uterine artery ligation for PPH. The blood samples will be centrifuged within 2 hours after being obtained and assessed on the same day. AMH concentrations will be measured with an enzymatically amplified two-sided immunoassay

Locations
Country Name City State
Turkey Pinar Yalcin Bahat Istanbul I?stanbul

Sponsors (1)
Lead Sponsor Collaborator
Kanuni Sultan Suleyman Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome
Type Measure Description Time frame Safety issue
Primary 1- Anti-Mullerian Hormone levels variation Anti-Mullerian Hormone levels before and 3 months after surgery 3 months
See also
  Status Clinical Trial Phase
Completed NCT03680339 - The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS Phase 4
Completed NCT03693599 - Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean Phase 4
Completed NCT03707132 - Tourniquet Reduces Blood Loss in Postpartum Hemorrhage During Hysterectomy for Placenta Accreta
Recruiting NCT02306733 - Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally Phase 3
Completed NCT01866241 - Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage Phase 3
Not yet recruiting NCT01236482 - Oxytocin in Cesarean Delivery Phase 4
Completed NCT03784794 - Patient Blood Management for Massive Obstetric Hemorrhage N/A
Enrolling by invitation NCT06255496 - QStat Cartridge in Obstetric Patients
Recruiting NCT04401839 - Amr Maneuver for Prevention of Postpartum Hemorrhage N/A
Recruiting NCT06219538 - DAISY Uterine Drain Device Evaluation N/A
Not yet recruiting NCT06333340 - Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery N/A
Completed NCT01863706 - Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage Phase 1
Terminated NCT04277962 - Estimating Blood Loss Using TritonTM in Vaginal Deliveries: A Validation Trial N/A
Completed NCT04723979 - NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL
Completed NCT03570723 - Glove-loaded Foley's Catheter Tamponade for Cesarean Section for Placenta Previa N/A
Completed NCT03117647 - Mansoura-VV Uterine Compression Suture for Primary Atonic Postpartum Hemorrhage N/A
Active, not recruiting NCT03069859 - Use of TXA to Prevent Postpartum Hemorrhage Phase 2
Not yet recruiting NCT03891082 - A Comparative Study Between Bakri Balloon and B Lynch Suture Used to Control Primary Postpartum Hemorrhage After Cesarean Section N/A
Not yet recruiting NCT03463070 - Misoprostol Before and After Cesarean Section Phase 3
Recruiting NCT05532215 - Sublingual Misoprostol in Reduction of Caesarean Blood Loss N/A